Adult stem cell products could be lining up to penetrate the inflammation and orthopedics markets, judging by the recent $1.38 billion paid by Genzyme for Osiris's mesenchymal stem cell technology.
The second goal was to seal those samples within the craft for the long journey back to Earth in order to safely bring them down through our planet's atmosphere. In other words, OSIRIS-REx was ...